Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Sorrento Announces Drilling Contract & Receives Permit to Drill Bottom Brook Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Lexeo Therapeutics Inc LXEO

Healthcare Biotechnology
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver... see more

Recent & Breaking News (NDAQ:LXEO)

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

GlobeNewswire 3 days ago

Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy

GlobeNewswire 7 days ago

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 22, 2025

Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum

GlobeNewswire December 4, 2025

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

GlobeNewswire November 5, 2025

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering

GlobeNewswire October 20, 2025

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

GlobeNewswire October 16, 2025

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire October 16, 2025

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

GlobeNewswire October 7, 2025

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

GlobeNewswire August 14, 2025

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

GlobeNewswire July 7, 2025

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

GlobeNewswire June 24, 2025

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

GlobeNewswire May 27, 2025

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

GlobeNewswire May 12, 2025

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

GlobeNewswire May 1, 2025

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

GlobeNewswire April 7, 2025

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

GlobeNewswire March 24, 2025

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2025

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

GlobeNewswire December 19, 2024

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

GlobeNewswire November 13, 2024

Podcasts